Fuan Pharmaceutical Group Co Total Assets

Latest as of March 2026: CN¥5.63 Billion CNY ≈ $824.31 Million USD

Fuan Pharmaceutical Group Co total assets. Based on the latest financial reports, Fuan Pharmaceutical Group Co (300194) holds total assets worth CN¥5.63 Billion CNY (≈ $824.31 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300194 market cap for the company's overall valuation and market capitalisation.

Total Assets of Fuan Pharmaceutical Group Co (2007–2025)

Total assets of Fuan Pharmaceutical Group Co from 2007 to 2025. This chart illustrates how Fuan Pharmaceutical Group Co's total assets have evolved over time, based on quarterly financial data. See 300194 stock price and chart for real-time trading data and today's change.

Fuan Pharmaceutical Group Co - Asset Composition Analysis

Fuan Pharmaceutical Group Co Total Assets Breakdown (December 2025)

Fuan Pharmaceutical Group Co total assets breakdown as of December 2025. Fuan Pharmaceutical Group Co's total assets of CN¥5.63 Billion consist of 33.8% current assets and 66.2% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 15.4%
Accounts Receivable CN¥151.23 Million 2.6%
Inventory CN¥643.05 Million 11.2%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥574.87 Million 10.0%
Goodwill CN¥132.16 Million 2.3%

Asset Composition Trend (2007–2025)

This chart illustrates how Fuan Pharmaceutical Group Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Fuan Pharmaceutical Group Co (300194) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Fuan Pharmaceutical Group Co's current assets represent 33.8% of total assets in 2025, a decrease from 45.1% in 2007.
  • Cash Position: Cash and equivalents constituted 15.4% of total assets in 2025, up from 7.7% in 2007.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 8.0% in 2007.
  • Asset Diversification: The largest asset category is inventory at 11.2% of total assets.

Fuan Pharmaceutical Group Co Competitors by Total Assets

Key competitors of Fuan Pharmaceutical Group Co based on total assets are shown below.

Company Country Total Assets
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
China CN¥68.33 Billion
Sandoz Group AG
SW:SDZ
Switzerland CHF22.86 Billion
H Lundbeck A/S
CO:HLUN-B
Denmark Dkr54.01 Billion
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥30.77 Billion
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
China CN¥17.01 Billion
Kangmei Pharmaceutical Co Ltd
SHG:600518
China CN¥13.68 Billion
Viyash Scientific Limited
NSE:SEQUENT
India Rs17.26 Billion
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
China CN¥5.11 Billion

Fuan Pharmaceutical Group Co - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.25 2.01 1.72
Quick Ratio 1.44 1.27 1.12
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥1.01 Billion CN¥1.09 Billion CN¥745.08 Million

Fuan Pharmaceutical Group Co - Advanced Valuation Insights

This section examines the relationship between Fuan Pharmaceutical Group Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.03
Latest Market Cap to Assets Ratio 0.11
Asset Growth Rate (YoY) -3.6%
Total Assets CN¥5.76 Billion
Market Capitalization $645.88 Million USD

Valuation Analysis

Below Book Valuation: The market values Fuan Pharmaceutical Group Co's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Fuan Pharmaceutical Group Co's assets decreased by 3.6% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Fuan Pharmaceutical Group Co (2007–2025)

The table below shows the annual total assets of Fuan Pharmaceutical Group Co from 2007 to 2025.

Year Total Assets Change
2025-12-31 CN¥5.76 Billion
≈ $843.37 Million
-3.60%
2024-12-31 CN¥5.98 Billion
≈ $874.85 Million
+0.04%
2023-12-31 CN¥5.98 Billion
≈ $874.47 Million
+1.67%
2022-12-31 CN¥5.88 Billion
≈ $860.13 Million
+3.01%
2021-12-31 CN¥5.71 Billion
≈ $835.03 Million
-4.46%
2020-12-31 CN¥5.97 Billion
≈ $874.01 Million
+26.12%
2019-12-31 CN¥4.74 Billion
≈ $693.02 Million
+10.33%
2018-12-31 CN¥4.29 Billion
≈ $628.14 Million
-8.45%
2017-12-31 CN¥4.69 Billion
≈ $686.12 Million
+6.62%
2016-12-31 CN¥4.40 Billion
≈ $643.51 Million
+77.39%
2015-12-31 CN¥2.48 Billion
≈ $362.77 Million
+35.31%
2014-12-31 CN¥1.83 Billion
≈ $268.11 Million
-1.67%
2013-12-31 CN¥1.86 Billion
≈ $272.67 Million
+3.25%
2012-12-31 CN¥1.80 Billion
≈ $264.10 Million
-0.68%
2011-12-31 CN¥1.82 Billion
≈ $265.90 Million
+424.97%
2010-12-31 CN¥346.14 Million
≈ $50.65 Million
+26.50%
2009-12-31 CN¥273.62 Million
≈ $40.04 Million
+35.06%
2008-12-31 CN¥202.59 Million
≈ $29.64 Million
+150.45%
2007-12-31 CN¥80.89 Million
≈ $11.84 Million
--

About Fuan Pharmaceutical Group Co

SHE:300194 China Drug Manufacturers - Specialty & Generic
Market Cap
$645.88 Million
CN¥4.41 Billion CNY
Market Cap Rank
#10670 Global
#2861 in China
Share Price
CN¥3.71
Change (1 day)
+0.82%
52-Week Range
CN¥3.34 - CN¥4.76
All Time High
CN¥10.53
About

Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China and internationally. It offers APIs; intermediates; and FDFs, such as anti-tumor, specialty drugs, antibiotics, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) … Read more